Constitutive activation of the transcription factor NRF2 confers therapeutic resistance in glioblastoma (GBM), however, this hyperactivation frequently persists despite the presence of intact KEAP1, suggesting the existence of KEAP1-independent regulatory mechanisms. The gene discussed is KEAP1; the disease is glioblastoma.